Cargando…
Evaluation of tumour hypoxia during radiotherapy using [(18)F]HX4 PET imaging and blood biomarkers in patients with head and neck cancer
BACKGROUND AND PURPOSE: Increased tumour hypoxia is associated with a worse overall survival in patients with head and neck squamous cell carcinoma (HNSCC). The aims of this study were to evaluate treatment-associated changes in [(18)F]HX4-PET, hypoxia-related blood biomarkers, and their interdepend...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5047929/ https://www.ncbi.nlm.nih.gov/pubmed/27251643 http://dx.doi.org/10.1007/s00259-016-3429-y |
_version_ | 1782457499905949696 |
---|---|
author | Zegers, Catharina M. L. Hoebers, Frank J. P. van Elmpt, Wouter Bons, Judith A. Öllers, Michel C. Troost, Esther G. C. Eekers, Daniëlle Balmaekers, Leo Arts-Pechtold, Marlies Mottaghy, Felix M. Lambin, Philippe |
author_facet | Zegers, Catharina M. L. Hoebers, Frank J. P. van Elmpt, Wouter Bons, Judith A. Öllers, Michel C. Troost, Esther G. C. Eekers, Daniëlle Balmaekers, Leo Arts-Pechtold, Marlies Mottaghy, Felix M. Lambin, Philippe |
author_sort | Zegers, Catharina M. L. |
collection | PubMed |
description | BACKGROUND AND PURPOSE: Increased tumour hypoxia is associated with a worse overall survival in patients with head and neck squamous cell carcinoma (HNSCC). The aims of this study were to evaluate treatment-associated changes in [(18)F]HX4-PET, hypoxia-related blood biomarkers, and their interdependence. MATERIAL AND METHODS: [(18)F]HX4-PET/CT scans of 20 patients with HNSCC were acquired at baseline and after ±20Gy of radiotherapy. Within the gross-tumour-volumes (GTV; primary and lymph nodes), mean and maximum standardized uptake values, the hypoxic fraction (HF) and volume (HV) were calculated. Also, the changes in spatial uptake pattern were evaluated using [(18)F]HX4-PET/CT imaging. For all patients, the plasma concentration of CAIX, osteopontin and VEGF was assessed. RESULTS: At baseline, tumour hypoxia was detected in 69 % (22/32) of the GTVs. During therapy, we observed a significant decrease in all image parameters. The HF decreased from 21.7 ± 19.8 % (baseline) to 3.6 ± 10.0 % (during treatment; P < 0.001). Only two patients had a HV > 1 cm(3) during treatment, which was located for >98 % within the baseline HV. During treatment, no significant changes in plasma CAIX or VEGF were observed, while osteopontin was increased. CONCLUSIONS: [(18)F]HX4-PET/CT imaging allows monitoring changes in hypoxia during (chemo)radiotherapy whereas the blood biomarkers were not able to detect a treatment-associated decrease in hypoxia. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00259-016-3429-y) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5047929 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-50479292016-10-18 Evaluation of tumour hypoxia during radiotherapy using [(18)F]HX4 PET imaging and blood biomarkers in patients with head and neck cancer Zegers, Catharina M. L. Hoebers, Frank J. P. van Elmpt, Wouter Bons, Judith A. Öllers, Michel C. Troost, Esther G. C. Eekers, Daniëlle Balmaekers, Leo Arts-Pechtold, Marlies Mottaghy, Felix M. Lambin, Philippe Eur J Nucl Med Mol Imaging Original Article BACKGROUND AND PURPOSE: Increased tumour hypoxia is associated with a worse overall survival in patients with head and neck squamous cell carcinoma (HNSCC). The aims of this study were to evaluate treatment-associated changes in [(18)F]HX4-PET, hypoxia-related blood biomarkers, and their interdependence. MATERIAL AND METHODS: [(18)F]HX4-PET/CT scans of 20 patients with HNSCC were acquired at baseline and after ±20Gy of radiotherapy. Within the gross-tumour-volumes (GTV; primary and lymph nodes), mean and maximum standardized uptake values, the hypoxic fraction (HF) and volume (HV) were calculated. Also, the changes in spatial uptake pattern were evaluated using [(18)F]HX4-PET/CT imaging. For all patients, the plasma concentration of CAIX, osteopontin and VEGF was assessed. RESULTS: At baseline, tumour hypoxia was detected in 69 % (22/32) of the GTVs. During therapy, we observed a significant decrease in all image parameters. The HF decreased from 21.7 ± 19.8 % (baseline) to 3.6 ± 10.0 % (during treatment; P < 0.001). Only two patients had a HV > 1 cm(3) during treatment, which was located for >98 % within the baseline HV. During treatment, no significant changes in plasma CAIX or VEGF were observed, while osteopontin was increased. CONCLUSIONS: [(18)F]HX4-PET/CT imaging allows monitoring changes in hypoxia during (chemo)radiotherapy whereas the blood biomarkers were not able to detect a treatment-associated decrease in hypoxia. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00259-016-3429-y) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2016-06-01 2016 /pmc/articles/PMC5047929/ /pubmed/27251643 http://dx.doi.org/10.1007/s00259-016-3429-y Text en © The Author(s) 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Article Zegers, Catharina M. L. Hoebers, Frank J. P. van Elmpt, Wouter Bons, Judith A. Öllers, Michel C. Troost, Esther G. C. Eekers, Daniëlle Balmaekers, Leo Arts-Pechtold, Marlies Mottaghy, Felix M. Lambin, Philippe Evaluation of tumour hypoxia during radiotherapy using [(18)F]HX4 PET imaging and blood biomarkers in patients with head and neck cancer |
title | Evaluation of tumour hypoxia during radiotherapy using [(18)F]HX4 PET imaging and blood biomarkers in patients with head and neck cancer |
title_full | Evaluation of tumour hypoxia during radiotherapy using [(18)F]HX4 PET imaging and blood biomarkers in patients with head and neck cancer |
title_fullStr | Evaluation of tumour hypoxia during radiotherapy using [(18)F]HX4 PET imaging and blood biomarkers in patients with head and neck cancer |
title_full_unstemmed | Evaluation of tumour hypoxia during radiotherapy using [(18)F]HX4 PET imaging and blood biomarkers in patients with head and neck cancer |
title_short | Evaluation of tumour hypoxia during radiotherapy using [(18)F]HX4 PET imaging and blood biomarkers in patients with head and neck cancer |
title_sort | evaluation of tumour hypoxia during radiotherapy using [(18)f]hx4 pet imaging and blood biomarkers in patients with head and neck cancer |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5047929/ https://www.ncbi.nlm.nih.gov/pubmed/27251643 http://dx.doi.org/10.1007/s00259-016-3429-y |
work_keys_str_mv | AT zegerscatharinaml evaluationoftumourhypoxiaduringradiotherapyusing18fhx4petimagingandbloodbiomarkersinpatientswithheadandneckcancer AT hoebersfrankjp evaluationoftumourhypoxiaduringradiotherapyusing18fhx4petimagingandbloodbiomarkersinpatientswithheadandneckcancer AT vanelmptwouter evaluationoftumourhypoxiaduringradiotherapyusing18fhx4petimagingandbloodbiomarkersinpatientswithheadandneckcancer AT bonsjuditha evaluationoftumourhypoxiaduringradiotherapyusing18fhx4petimagingandbloodbiomarkersinpatientswithheadandneckcancer AT ollersmichelc evaluationoftumourhypoxiaduringradiotherapyusing18fhx4petimagingandbloodbiomarkersinpatientswithheadandneckcancer AT troostesthergc evaluationoftumourhypoxiaduringradiotherapyusing18fhx4petimagingandbloodbiomarkersinpatientswithheadandneckcancer AT eekersdanielle evaluationoftumourhypoxiaduringradiotherapyusing18fhx4petimagingandbloodbiomarkersinpatientswithheadandneckcancer AT balmaekersleo evaluationoftumourhypoxiaduringradiotherapyusing18fhx4petimagingandbloodbiomarkersinpatientswithheadandneckcancer AT artspechtoldmarlies evaluationoftumourhypoxiaduringradiotherapyusing18fhx4petimagingandbloodbiomarkersinpatientswithheadandneckcancer AT mottaghyfelixm evaluationoftumourhypoxiaduringradiotherapyusing18fhx4petimagingandbloodbiomarkersinpatientswithheadandneckcancer AT lambinphilippe evaluationoftumourhypoxiaduringradiotherapyusing18fhx4petimagingandbloodbiomarkersinpatientswithheadandneckcancer |